A Randomized Double-Blind Comparative Study of YLB217 and Recombinant Darbepoetin alfa in Renal Anemia Patients on Hemodialysis
Phase 3
Completed
- Conditions
- Renal anemia
- Registration Number
- JPRN-jRCT2080225098
- Lead Sponsor
- YL Biologics Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 144
Inclusion Criteria
Renal anemia patients on hemodialysis with the age >= 20 years
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method